Standout Papers

The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes 2000 2026 2008 2017 1.3k
  1. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes (2000)
    David Altshuler, Joel N. Hirschhorn et al. Nature Genetics
  2. Hypertriglyceridemic Waist (2000)
    Isabelle Lemieux, Agnès Pascot et al. Circulation
  3. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial (2010)
    Frederick J. Raal, Raúl D. Santos et al. The Lancet
  4. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (2014)
    Frederick J. Raal, Evan A. Stein et al. The Lancet
  5. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study (2012)
    Marina Cuchel, Emma A. Meagher et al. The Lancet
  6. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial (2012)
    Evan A. Stein, Jean Bergeron et al. The Lancet
  7. Evinacumab for Homozygous Familial Hypercholesterolemia (2020)
    Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine
  8. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia (2015)
    Daniel Gaudet, Veronica J. Alexander et al. New England Journal of Medicine
  9. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019)
    Joseph L. Witztum, Daniel Gaudet et al. New England Journal of Medicine
  10. Targeting APOC3 in the Familial Chylomicronemia Syndrome (2014)
    Daniel Gaudet, Diane Brisson et al. New England Journal of Medicine
  11. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance (2019)
    Ulrich Laufs, Maciej Banach et al. Journal of the American Heart Association
  12. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (2022)
    Michelle L. O’Donoghue, Robert S. Rosenson et al. New England Journal of Medicine
  13. Evinacumab in Patients with Refractory Hypercholesterolemia (2020)
    Robert S. Rosenson, Lesley Burgess et al. New England Journal of Medicine
  14. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk (2021)
    Jean‐Claude Tardif, Ewa Karwatowska‐Prokopczuk et al. European Heart Journal
  15. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia (2024)
    Christie M. Ballantyne, Szilárd Vasas et al. New England Journal of Medicine
  16. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk (2024)
    Brian A. Bergmark, Nicholas Marston et al. New England Journal of Medicine
  17. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia (2024)
    Robert S. Rosenson, Daniel Gaudet et al. New England Journal of Medicine
  18. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia (2024)
    Daniel Gaudet, Dénes Páll et al. JAMA Cardiology
  19. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk (2024)
    Gerald F. Watts, Robert S. Rosenson et al. New England Journal of Medicine

Immediate Impact

11 by Nobel laureates 23 from Science/Nature 86 standout
Sub-graph 1 of 17

Citing Papers

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2025 Standout
Lipoprotein(a) and cardiovascular disease
2024 Standout
19 intermediate papers

Works of Daniel Gaudet being referenced

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
2022 Standout
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
2010 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Daniel Gaudet 8375 5331 5688 408 18.2k
Jean Davignon 9842 3704 5411 267 19.2k
Robert A. Hegele 9954 7761 7534 719 25.9k
Florian Kronenberg 6302 3306 3431 375 19.7k
Santica M. Marcovina 12070 4928 11179 405 24.6k
Christian Ehnholm 9150 4472 9651 375 21.3k
Anne Tybjærg‐Hansen 10644 7161 9027 341 27.4k
Kausik K. Ray 13980 6441 9730 450 25.2k
Sergio Fazio 6322 4242 6517 308 19.8k
Eric J.G. Sijbrands 4966 3014 2998 274 12.1k
Éric Bruckert 7463 3254 5326 378 17.1k

All Works

Loading papers...

Rankless by CCL
2026